drugset / Trial / NCT06409390
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
NaSequentialOpen-labelTreatment
Summary
The purpose of the study is to test a treatment strategy with currently approved drugs to see if it is practical to administer the available drugs in a new way that researchers hope could be more effective in treating metastatic breast cancer.
Timeline
- Start
- 2024-08-14
- Primary completion
- 2027-04
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 150 mg | Oral |
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Cyclophosphamide | Other / unclassified | 600 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | — |
| Subject | Fulvestrant | Small molecule | 500 mg | Intramuscular |
| Subject | Ribociclib | Small molecule | 600 mg | Oral |
| Subject | Sacituzumab Govitecan | Monoclonal antibody | 10 mg/kg | — |
| Subject | Trastuzumab deruxtecan | Monoclonal antibody | 5.4 mg/kg | — |